nci_id	nct_id	official_title	inclusion_indicaInclusionor	description	Text	Boolean
NCI-2009-00336	NCT00392327	Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-apoptotic Agent in Other than Average Risk Medulloblastoma/PNET Patients	N/A			
NCI-2009-00470	NCT00632853	Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and Etoposide	N/A			
NCI-2009-00595	NCT00719303	Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?	N/A			
NCI-2009-00603	NCT00492778	A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus	N/A			
NCI-2009-00817	NCT00001337	Dose-Adjusted EPOCH Chemotherapy and Rituximab (Cd20+) in Adults and Children with Previously Untreated Aggressive Non-Hodgkin's Lymphoma	N/A			
NCI-2009-01057	NCT00576654	A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients with Advanced Solid Tumors	N/A			
NCI-2011-00312	NCT01012817	A Phase 1/2 Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients with Solid Tumors (Phase 1) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase 2) after Prior Platinum Containing First-Line Chemotherapy	N/A			
NCI-2011-00878	NCT00956007	A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer	N/A			
NCI-2011-01915	NCT00887146	N0577 (CODEL): Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma	N/A			
NCI-2011-01972	NCT00983697	A Multicenter Trial of FDG-PET/CT Staging of Head and Neck Cancer and Its Impact on the N0 Neck Surgical Treatment in Head and Neck Cancer Patients	N/A			
NCI-2011-01973	NCT00980954	Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma following Radical Hysterectomy	N/A			
NCI-2011-01974	NCT00981656	A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy following a Thorough Transurethral Surgical Re-staging	Inclusion	White blood cell count (WBC) >= 4,000/ml	Leukocyte count greater than or equal to 4000 per mililiter	(C51948 >= 4000/mL)
NCI-2011-01975	NCT00980460	Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment	N/A			
NCI-2011-01987	NCT01013649	A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma	N/A			
NCI-2011-01992	NCT02085408	Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)	N/A			
NCI-2011-02000	NCT01042522	A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary	N/A			
NCI-2011-02029	NCT01096368	Phase III Randomized Trial of Post-radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years	N/A			
NCI-2011-02034	NCT01118026	Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)	N/A			
NCI-2011-02037	NCT01101451	Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy	N/A			
NCI-2011-02073	NCT02589938	A Phase III Prospective Randomized Trial of Acupuncture for Treatment_x000D_ of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer	N/A			
NCI-2011-02500	NCT01366144	An Early Phase 1 Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Patients with Hepatic or Renal Dysfunction and Solid Tumors	N/A			
NCI-2011-02515	NCT01051635	A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults with Relapsed Solid Tumors and Lymphomas	N/A			
NCI-2011-02539	NCT01226940	A Phase I Trial of Lenalidomide and Radiotherapy in Children with Diffuse Intrinsic Pontine Gliomas and High-Grade Gliomas	N/A			
NCI-2011-02592	NCT01386385	A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)	N/A			
NCI-2011-02594	NCT01381718	A Phase II Placebo-Controlled Trial of Modafinil to Improve_x000D_ Neurocognitive Deficits in Children Treated for a Primary Brain Tumor	N/A			
NCI-2011-02599	NCT01190930	Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)	Inclusion	B-ALL patients must have an initial white blood cell count < 50,000/uL	 initial white blood cell count less than 50,000 per microliter	(C8644 = YES) AND (C51948 <= 50000/uL) OR (C8644 = NO)
NCI-2011-02611	NCT01231906	A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma	N/A			
NCI-2011-02623	NCT01272037	A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer	N/A			
NCI-2011-02660	NCT01275664	Pilot Study of Standard Therapy for Prevention of Nausea and Emesis Associated with First Line Post-Operative Intraperitoneal Chemotherapy	N/A			
NCI-2011-02673	NCT01359592	A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL)	N/A			
NCI-2011-02674	NCT01368588	Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial	N/A			
NCI-2011-03458	NCT01434316	Phase 1 Trial of ABT-888 and SCH727965 in Patients with Advanced Solid Tumors	N/A			
NCI-2011-03797	NCT02883049	A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) including a Stratum Evaluating Dasatinib (NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations	Inclusion	White Blood Cell Count (WBC) Criteria  * Age 1-9.99 years: WBC >= 50 000/uL   * Age 10-30.99 years: Any WBC   * Age 1-30.99 years: Any WBC with:  ** Testicular leukemia  ** CNS leukemia (CNS3)  ** Steroid pretreatment	between age 1 and 9.99 white blood count greater than or equal to 50000 / uL , between age 10 and 31.99 any white blood count, between age 1 and 31.99 any white blood count with testicular leukemia, CNS leukemia, or steroid treatment	(C25150>= 1 a AND C25150 < 10 a AND C51948 >= 50000/ uL) OR (C25150 >= 10 a AND C25150 < 31 a ) OR (C25150 >= 1 a AND C25150 < 31 a  AND ( C9277 = YES OR C5440 = YES OR C15370 = YES) 
NCI-2012-00095	NCT01497444	Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in 1st Line Advanced HCC	N/A			
NCI-2012-00105	NCT01503632	A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL	N/A			
NCI-2012-00112	NCT01503086	Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study	N/A			
NCI-2012-00234	NCT01515787	A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision	N/A			
NCI-2012-00680	NCT01333046	Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients with Active or Relapsed Hodgkin or Non-Hodgkin Lymphoma	N/A			
NCI-2012-00707	NCT01556243	Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)	N/A			
NCI-2012-00719	NCT01573442	Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias	Inclusion	White blood cell (WBC) > 3.0	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2012-00860	NCT01587352	A Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2012-00864	NCT01585805	A Randomized Phase II Study of Gemcitabine, Cisplatin +/- Veliparib in Patients with  Pancreas Adenocarcinoma and a Known BRCA/ PALB2 Mutation (Part I) and a Phase II Single Arm Study of Single-Agent Veliparib in Previously Treated Pancreas Adenocarcinoma (Part II)	N/A			
NCI-2012-01040	NCT01638533	A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients with, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction	N/A			
NCI-2012-01695	NCT01775475	Randomized, Phase II Trial of CHOP vs. Oral Chemotherapy with Concomitant Antiretroviral Therapy in Patients with HIV-Associated Lymphoma in Sub-Saharan Africa	Inclusion	White blood cells (WBC) >= 3,000 cells/uL (3.0 x 10^9 L) or	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2012-01712	NCT01695941	A Phase I Study of MLN8237 in Combination with Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2012-01964	NCT01595061	A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061)	N/A			
NCI-2012-01967	NCT01602666	Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)	N/A			
NCI-2012-01977	NCT01622868	Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer: A Collaborative Study of NRG Oncology and KROG	N/A			
NCI-2012-01990	NCT01649089	Evaluation of Physical Function and Quality of Life (QOL) before and after Non-radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (â‰¤ 2CM) Cervical Cancer	N/A			
NCI-2012-01995	NCT01674140	Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer. e^3 Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy.	N/A			
NCI-2012-01998	NCT01668719	A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)	N/A			
NCI-2012-02009	NCT01711541	Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) - a Phase 1/Randomized Phase 2 Study in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck	Inclusion	Leukocytes >= 3,000/mm^3	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2012-02011	NCT01711554	A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients with Refractory/Recurrent Neuroblastoma	N/A			
NCI-2012-02020	NCT01781468	A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (NuvigilÂ®) to_x000D_ Reduce Cancer-Related Fatigue in Patients with High Grade Glioma	N/A			
NCI-2012-02045	NCT01805076	Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer	N/A			
NCI-2012-02057	NCT01730937	Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma	N/A			
NCI-2012-02067	NCT01349881	A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III- Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)	Inclusion	Total white blood cells (WBC) >= 4.0 x 10^3/mcL	Leukocyte count greater than or equal to 4000 per microliter	(C51948 >= 4000/uL)
NCI-2012-02078	NCT01789684	A Cluster Randomized Controlled Trial Comparing Interventions to Enhance Utilization of Genetics_x000D_ Services Among Breast Cancer Patients	N/A			
NCI-2012-02608	NCT01863550	Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)	N/A			
NCI-2012-02767	NCT01749397	A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 with Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers	N/A			
NCI-2012-02869	NCT01806129	EROS: Engendering Reproductive Health within Oncologic Survivorship	N/A			
NCI-2012-02875	NCT01586403	Transfer of Genetically Engineered Lymphocytes in Melanoma Patients: A Phase 1 Dose Escalation Study	N/A			
NCI-2012-03124	NCT01755195	A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients with Metastatic Refractory Soft Tissue Sarcoma	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2012-03125	NCT01767194	A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (Ch14.18) (NSC# 764038) in Children with Refractory, Relapsed or Progressive Neuroblastoma	N/A			
NCI-2012-03173	NCT01089101	A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma	N/A			
NCI-2012-03198	NCT01872975	A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy	N/A			
NCI-2013-00046	NCT01771107	A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma	N/A			
NCI-2013-00370	NCT01220583	A Randomized Phase II / Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors	N/A			
NCI-2013-00426	NCT01824836	A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)	N/A			
NCI-2013-00500	NCT01810913	Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck	N/A			
NCI-2013-00595	NCT01817075	Impact of Cleansing with Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children with Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT)	N/A			
NCI-2013-00716	NCT00978250	Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine (FdCyd + THU)	N/A			
NCI-2013-00737	NCT01822496	A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)	N/A			
NCI-2013-00739	NCT01822509	A Phase I/Ib Study of Ipilimumab or Nivolumab in Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation	N/A			
NCI-2013-00740	NCT01822522	Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons with HIV Infection	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2013-00805	NCT01244737	A Phase II Study of [18F] FLT for PET Imaging of Brain Tumors in Children	N/A			
NCI-2013-00826	NCT01841723	A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia	N/A			
NCI-2013-00858	NCT01849146	Phase I Study of AZD1775 (MK-1775) with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients with Recurrent Glioblastoma	N/A			
NCI-2013-00875	NCT01901094	A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy	N/A			
NCI-2013-00877	NCT01851369	A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination with Temozolomide in Patients with Relapsed Solid Tumors and Lymphomas	N/A			
NCI-2013-00890	NCT01935934	A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer	N/A			
NCI-2013-00998	NCT01881867	A Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) after Completion of Standard FDA Approved Therapy with Sipuleucel-T (ProvengeÂ®) for Patients with Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer (mCRPC)	N/A			
NCI-2013-01132	NCT01534598	Phase I Trial of Oral 5-Fluoro-2'-Deoxycytidine with Oral Tetrahydrouridine in Patients with Advanced Solid Tumors	N/A			
NCI-2013-01272	NCT01897012	A Phase 1 Trial of MLN8237 plus Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas	N/A			
NCI-2013-01275	NCT01896999	A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma	N/A			
NCI-2013-01320	NCT01902173	Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination with Dabrafenib and Trametinib in Patients with BRAF Mutant Cancer	N/A			
NCI-2013-01340	NCT01953588	ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study	N/A			
NCI-2013-01357	NCT01912625	A Phase 1 Study of Trametinib in Combination with Chemoradiation for KRAS Mutant Non-small Cell Lung Cancer	N/A			
NCI-2013-01368	NCT01925131	A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients with Relapsed/Refractory CD22-Positive Acute Leukemia (including B-ALL, Mixed Phenotypic Leukemia and Burkitt's Leukemia)	N/A			
NCI-2013-01452	NCT00942877	Phase II Study of Cediranib (AZD2171) in Patients with Alveolar Soft Part Sarcoma	N/A			
NCI-2013-01474	NCT01273155	Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2013-01475	NCT01273168	Phase I Trial of Z-Endoxifen in Adults with Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or Other Hormone Receptor-Positive Solid Tumors	N/A			
NCI-2013-01491	NCT01362803	A Phase I/II Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor Selumetinib (AZD6244; HYD Sulfate) in Children with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)	N/A			
NCI-2013-01496	NCT01391962	A Phase II Trial in Which Patients with Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, with Cross-Over at Disease Progression	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2013-01520	NCT01572493	A Phase I Study of a Continuous Intravenous Infusion of Recombinant Human IL-15 (rhIL-15) in Adults with Metastatic Cancers	N/A			
NCI-2013-01568	NCT01748825	A Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Inhibitor, in Patients with Advanced Refractory Solid Tumors	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2013-01588	NCT01827384	Molecular Profiling-Based Assignment of Cancer Therapy for Patients with Advanced Solid Tumors	N/A			
NCI-2013-01602	NCT01922076	A Phase 1 Study of AZD1775 (MK-1775, IND# 116495) Concurrent with Local Radiation Therapy for the Treatment of Newly Diagnosed Children with Diffuse Intrinsic Pontine Gliomas	N/A			
NCI-2013-01639	NCT01964300	Phase II Study of Peginterferon Alfa-2b (SYLATRON) for Pediatric Patients with Unresectable or Recurrent Craniopharyngioma	N/A			
NCI-2013-01702	NCT02004275	A Phase I/II Study of Pomalidomide, Dexamethasone, and Ixazomib vs.Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy	N/A			
NCI-2013-01703	NCT01940809	A Sequential Safety and Biomarker Study of BRAF-MEK Inhibition on the Immune Response in the Context of Combined CTLA-4 Blockade and PD-1 Blockade for BRAF Mutant Melanoma	N/A			
NCI-2013-01748	NCT01947023	A Phase 1 Study of Dabrafenib in Combination with Lapatinib in BRAF Mutant Thyroid Cancer	N/A			
NCI-2013-01760	NCT01988571	Preventing Anthracycline Cardiovascular Toxicity with Statins (PREVENT)	N/A			
NCI-2013-01850	NCT01993810	Phase III Randomized Trial Comparing Overall Survival after Photon versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC	N/A			
NCI-2013-01904	NCT02054741	A Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy or Similar Agents for Advanced Cancer: Reducing Toxicity in Older Adults	N/A			
NCI-2013-01999	NCT01946789	A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients with Advanced Solid Tumors: Melanoma, Renal Cell, Sarcoma, Colon, Non-Hodgkin Lymphoma, Non-small Cell Lung, Squamous Cell Head and Neck Cancer and Cutaneous Squamous Cell Cancer	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2013-02103	NCT01989585	Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma and Other Solid Tumors	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2013-02167	NCT01979536	A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL)	N/A			
NCI-2013-02229	NCT02003222	A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults	N/A			
NCI-2013-02238	NCT01896869	A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab in Combination with Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer	Inclusion	White blood cells (WBC) >= 3500/uL	Leukocyte count greater than or equal to 3500 per microliter	(C51948 >= 3500/uL)
NCI-2013-02284	NCT02065687	A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer	N/A			
NCI-2013-02288	NCT02059499	A Randomized, Phase III Study of Intra-anal Imiquimod 2.5 % vs. Topical 5-Fluorouracil 5% vs. Observation for the Treatment of High-Grade Anal Squamous Intraepithelial Lesions in HIV-Positive Men and Women	N/A			
NCI-2013-02426	NCT02029950	A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery following Induction Timed Sequential Chemotherapy with Cytarabine, Daunorubicin, and Etoposide (AcDVP16) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MDS	N/A			
NCI-2014-00115	NCT02015104	A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) Given in Combination with PANVACâ„¢ versus BCG Given Alone in Adults with High Grade Non-muscle Invasive Bladder Cancer (NMIBC) Who Failed at Least 1 Induction Course of BCG	N/A			
NCI-2014-00416	NCT02070549	A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients with Hepatic Dysfunction	N/A			
NCI-2014-00461	NCT02079740	An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects with KRAS or NRAS Mutation-Positive Advanced Solid Tumors	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2014-00547	NCT02095132	A Phase 1/2 Study of AZD1775 (MK-1775) in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors	N/A			
NCI-2014-00615	NCT02097225	Phase I Study of AT13387 in Combination with Dabrafenib and Trametinib in Patients with BRAF-Mutant Melanoma and Other Solid Tumors	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2014-00616	NCT02152982	A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation	N/A			
NCI-2014-00620	NCT02101775	A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination with AZD 1775 (MK 1775) in Women with Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2014-00623	NCT02143726	Randomized Phase II Study of Sorafenib with or without Everolimus in Patients with Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer	N/A			
NCI-2014-00627	NCT02154490	A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)	N/A			
NCI-2014-00629	NCT02101788	A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer	N/A			
NCI-2014-00631	NCT02101853	Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)	N/A			
NCI-2014-00634	NCT02101905	Drug Distribution and Pharmacodynamic Study of Pulsatile Lapatinib in Surgically Accessible EGFR-Amplified Recurrent High-Grade Glioma	N/A			
NCI-2014-00635	NCT02135042	Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)	N/A			
NCI-2014-00636	NCT02135419	ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study	N/A			
NCI-2014-00640	NCT02255461	Phase I Study of CDK 4-6 Inhibitor PD-0332991 in Children with Recurrent, Progressive or Refractory Central Nervous System Tumors	N/A			
NCI-2014-00643	NCT02101944	Pilot Trial Evaluating Viral Protein Production from the Combination of Reolysin and Carfilzomib in Multiple Myeloma	N/A			
NCI-2014-00644	NCT02032823	A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy	N/A			
NCI-2014-00677	NCT02176967	Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-high-risk Neuroblastoma	N/A			
NCI-2014-00686	NCT02152137	A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination with Paclitaxel in Patients with Advanced Anaplastic Thyroid Cancer	N/A			
NCI-2014-00688	NCT02379416	Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults with Refractory Solid Tumors	N/A			
NCI-2014-00702	NCT02206334	A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases	N/A			
NCI-2014-00712	NCT02112916	A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)	N/A			
NCI-2014-00746	NCT02115282	A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer	N/A			
NCI-2014-00804	NCT02116777	A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, plus Temozolomide in Children with Refractory or Recurrent Malignancies	N/A			
NCI-2014-00816	NCT02211755	Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults with Refractory Solid Tumors	N/A			
NCI-2014-00849	NCT02200042	Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma	N/A			
NCI-2014-00850	NCT02177695	A Randomized Phase II Study of Co-expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer	N/A			
NCI-2014-00852	NCT02190279	A Pilot Study of 18F-DCFBC PET/CT in Prostate Cancer	N/A			
NCI-2014-00907	NCT02133183	Pilot Study of MLN0128 (TAK-228) in Preoperative Recurrent Glioblastoma (GBM) Patients	N/A			
NCI-2014-01028	NCT02249949	A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients with Previously Treated, Unrespecatble Myxoid Liposarcoma	N/A			
NCI-2014-01043	NCT02143401	A Phase I Trial of ABT-263 (Navitoclax), a Bcl-2 Inhibitor, and Sorafenib (Nexavar) in Patients with Relapsed or Refractory Solid Organ Tumors	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2014-01047	NCT02143414	A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Postive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL with Known or Presumed Activating Dastinib-Sensitive Mutations or Kinase Fusions (DSMKF)	N/A			
NCI-2014-01072	NCT02179086	Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma	N/A			
NCI-2014-01106	NCT02152995	A Phase 2 Study of Trametinib in Combination with Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers	N/A			
NCI-2014-01107	NCT02159989	Phase I Study of MLN0128 (TAK-228) (NSC# 768435) in Combination with Ziv-Aflibercept (NSC# 724770) in Patients with Advanced Cancers	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2014-01118	NCT02142803	A Phase 1 Study of MLN0128 and Bevacizumab in Patients with Recurrent Glioblastoma and Other Solid Tumors	N/A			
NCI-2014-01222	NCT02304458	A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab	N/A			
NCI-2014-01223	NCT02166463	A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults	N/A			
NCI-2014-01340	NCT02180867	Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation plus or minus Pazopanib (NSC# 737754)	N/A			
NCI-2014-01470	NCT02196181	A Randomized Phase II Trial of Intermittent versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma	N/A			
NCI-2014-01497	NCT02270450	Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction	N/A			
NCI-2014-01507	NCT02201992	A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein	N/A			
NCI-2014-01508	NCT02193282	Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)	N/A			
NCI-2014-01696	NCT02375204	A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors	N/A			
NCI-2014-01747	NCT02224781	A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma	N/A			
NCI-2014-01754	NCT02203526	Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma	N/A			
NCI-2014-01810	NCT02364557	A Phase IIR/III Trial of  Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer	N/A			
NCI-2014-01820	NCT02445391	A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy	N/A			
NCI-2014-01927	NCT02243605	A Phase 2 Study of XL184 (Cabozantinib) in Treating Patients with Relapsed Osteosarcomas and Ewing Sarcomas	N/A			
NCI-2014-01984	NCT02298959	A Phase 1 Trial of MK-3475 plus Ziv-Aflibercept in Patients with Advanced Solid Tumors	Inclusion	Leukocytes >= 2,000/mcL	Leukocyte count greater than or equal to 2000 per microliter	(C51948 >= 2000/uL)
NCI-2014-02020	NCT02575794	Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients with Recurrent High Grade Glioma	N/A			
NCI-2014-02056	NCT02437851	A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons	Inclusion	Leukocytes: >= 3,000/mm^3	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2014-02167	NCT02275533	Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (Remain Trial)	Inclusion	Leukocytes >= 2,000/mcL	Leukocyte count greater than or equal to 2000 per microliter	(C51948 >= 2000/uL)
NCI-2014-02197	NCT02281760	A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients with BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease	N/A			
NCI-2014-02266	NCT02339740	A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid	N/A			
NCI-2014-02267	NCT02412670	A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma	N/A			
NCI-2014-02379	NCT02496208	A Phase 1 Study of Cabozantinib plus Nivolumab (CaboNivo) Alone or in Combination with Ipilimumab (CaboNivoIpi) in Patients with Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2014-02380	NCT02306161	Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma	N/A			
NCI-2014-02403	NCT02428192	A Phase 2 Study of Nivolumab and Ipilimumab in Advanced Leiomyosarcoma of the Uterus	N/A			
NCI-2014-02405	NCT02438722	A Randomized Phase II/III Trial of Afatinib plus Cetuximab versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC) (BI 1200.124)	N/A			
NCI-2014-02410	NCT02323880	A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors	N/A			
NCI-2014-02413	NCT02063828	Reducing Lung Cancer Survivors' Anxiety (RELAX)	N/A			
NCI-2014-02424	NCT02498600	Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	N/A			
NCI-2014-02474	NCT02317874	A Phase 1 Study of BMN 673 in Combination with Carboplatin and Paclitaxel in Patients with Advanced Solid Tumors	N/A			
NCI-2014-02559	NCT01885455	Improving Resection Rates Among African Americans with NSCLC ("Southern Lung Cancer Study")	N/A			
NCI-2014-02672	NCT02337517	Pilot Study for the Treatment of Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease (GVHD) with GDC-0449 (GDC-0449)	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2014-02674	NCT02339571	Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma	N/A			
NCI-2015-00030	NCT02360215	A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients with Brain Metastases	N/A			
NCI-2015-00052	NCT02799485	A Phase II Study of sEphB4-HSA in Kaposi Sarcoma	N/A			
NCI-2015-00054	NCT02465060	Molecular Analysis for Therapy Choice (MATCH)	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2015-00121	NCT03047213	An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2015-00127	NCT02535312	Phase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors, with Expansion Cohort in Mesothelioma / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin	N/A			
NCI-2015-00128	NCT02488967	A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer	N/A			
NCI-2015-00130	NCT02359565	A Safety and Preliminary Efficacy Trial of MK-3475 (Pembrolizumab; Anti-PD-1) in Children with Recurrent, Progressive or Refractory High-Grade Gliomas (HGG) and DIPGs and Hypermutated Brain Tumors	N/A			
NCI-2015-00159	NCT02363283	A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma	Inclusion	Leukocytes >= 3,000/uL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2015-00257	NCT02381548	A Phase 1 Study of AZD1775 in Combination with Belinostat in Relapsed and Refractory Myeloid Malignancies and Selected Untreated Patients with Acute Myeloid Leukemia	N/A			
NCI-2015-00258	NCT02381561	Phase I and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2'- Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Gastrointestinal Cancers	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2015-00260	NCT02500797	Randomized Phase II Study of Nivolumab with or without Ipilimumab in Patients with Metastatic or Unresectable Sarcoma	N/A			
NCI-2015-00323	NCT02516423	Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid versus Zoledronic Acid after Definite Radiation Therapy	N/A			
NCI-2015-00324	NCT02521493	Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome	N/A			
NCI-2015-00328	NCT02392429	Early Assessment of Treatment Response in AML Using FLT PET/CT Imaging	N/A			
NCI-2015-00378	NCT02659800	The Effect of IL-7 (CYT107) on CD4 Counts in Patients with High Grade Gliomas and Severe Treatment-Related CD4 Lymphopenia after Concurrent Radiation and Temozolomide	N/A			
NCI-2015-00383	NCT02398773	[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer	N/A			
NCI-2015-00456	NCT02407405	Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas	N/A			
NCI-2015-00461	NCT02408861	A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV-Associated Solid Tumors with Expansion Cohorts in HIV-Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma	Inclusion	Leukocytes >= 2,000/mm^3	Leukocyte count greater than or equal to 2000 per microliter	(C51948 >= 2000/uL)
NCI-2015-00537	NCT02588443	Phase I Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 plus Nab-paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 plus Nab-paclitaxel and Gemcitabine for Patients with Newly Diagnosed Resectable Pancreatic Carcinoma	N/A			
NCI-2015-00543	NCT02470091	Phase 2 Study of Denosumab (NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma	N/A			
NCI-2015-00545	NCT02417701	A Phase 2 Study of MLN0128 (TAK-228) in Patients with Advanced Squamous Cell Lung Cancers Harboring NFE2L2 and KEAP 1 Mutations	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2015-00546	NCT02523014	Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations	N/A			
NCI-2015-00547	NCT02595424	Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-small Cell Gastroenteropancreatic  Neuroendocrine Carcinomas	Inclusion	Leukocytes >= 3,000/mm^3	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2015-00606	NCT02446600	A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	N/A			
NCI-2015-00651	NCT02502266	A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)	N/A			
NCI-2015-00668	NCT02443077	A Randomized Double-Blind Phase III Study of Ibrutinib during and following Autologous Stem Cell Transplantation versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype	N/A			
NCI-2015-00695	NCT02423057	Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients with Advanced Solid Tumors	N/A			
NCI-2015-00741	NCT02453620	A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2015-00744	NCT02564198	A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors	N/A			
NCI-2015-00835	NCT02466971	A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer	N/A			
NCI-2015-00866	NCT02474173	Phase 1b Study of HSP90 Inhibitor, AT13387 in Combination with Paclitaxel in Patients with Advanced, Triple Negative Breast Cancer	Inclusion	Leukocytes >= 2,000/uL	Leukocyte count greater than or equal to 2000 per microliter	(C51948 >= 2000/uL)
NCI-2015-01000	NCT02484430	A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)	Exclusion	Patients with white blood cell (WBC) > 30,000 are not eligible to start therapy;	Leukocyte count less than or equal to 30000 per microliter	(C51948 <= 30000/uL)
NCI-2015-01001	NCT02484443	A Phase 2 Study of Human-Mouse Chimeric Anti-disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma	N/A			
NCI-2015-01053	NCT02496663	A Phase I Trial of AZD9291 and Necitumumab in EGFR-Mutant Non-small Cell Lung Cancer after Progression on a Previous EGFR Tyrosine Kinase Inhibitor	N/A			
NCI-2015-01097	NCT02498613	A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2015-01098	NCT02503709	A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) Inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT7519M in Patients with Advanced Solid Tumors	N/A			
NCI-2015-01139	NCT02503722	A Phase 1 Trial of MLN0128 in Combination with AZD9291 in Advanced EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC) after Progression on a Previous EGFR Tyrosine Kinase Inhibitor	N/A			
NCI-2015-01144	NCT02613364	A Randomized Clinical Trial Comparing the Effectiveness of Yoga, Survivorship Health Education, and Cognitive Behavioral Therapy for Treating Insomnia in Cancer Survivors	N/A			
NCI-2015-01178	NCT02308085	A Study Evaluating the Pregnancy Outcomes and Safety of_x000D_ Interrupting Endocrine Therapy for Young Women with_x000D_ Endocrine Responsive Breast Cancer Who Desire Pregnancy	N/A			
NCI-2015-01236	NCT02562716	A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma	N/A			
NCI-2015-01270	NCT02520778	A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-Mutant Non-small Cell Lung Cancer following Resistance to Initial EGFR Kinase Inhibitor	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2015-01271	NCT02520791	A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2015-01348	NCT02490878	Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases	N/A			
NCI-2015-01408	NCT02535325	A Phase I Study of Methoxyamine Combined with Chemo-radiation for Locally Advanced Non-squamous Non-small Cell Lung Cancer	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2015-01411	NCT02535338	A Phase 1/2 Trial of Erlotinib and Onalespib Lactate in EGFR-Mutant Non-small Cell Lung Cancer	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2015-01548	NCT02635009	Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer	N/A			
NCI-2015-01640	NCT02568553	A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)	N/A			
NCI-2015-01642	NCT02567409	A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX-970 in Metastatic Urothelial Carcinoma	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2015-01643	NCT02567422	A Phase I Study of VX-970 in Combination with Cisplatin and XRT in Patients with Locally Advanced HPV (-) Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2015-01644	NCT02567435	A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) versus VAC/VI plus Temsirolimus (TORI, Torisel, NSC# 683864, IND#122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)	N/A			
NCI-2015-01681	NCT02572453	Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL	N/A			
NCI-2015-01706	NCT02749903	A Phase II Study of Enzalutamide (NSC# 766085) for Patients with Androgen Receptor Positive Salivary Cancers	N/A			
NCI-2015-01707	NCT02761057	A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)	Inclusion	White blood cell count (WBC) >= 2,000/mcL	Leukocyte count greater than or equal to 2000 per microliter	(C51948 >= 2000/uL)
NCI-2015-01744	NCT02581930	A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers with Response and Resistance	N/A			
NCI-2015-01745	NCT02797470	A Phase I Study of Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-selected CD34+ Cells	N/A			
NCI-2015-01779	NCT02589522	Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of VX-970 When Combined with Whole Brain Radiotherapy (WBRT) in Patients with Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2015-01906	NCT02595866	Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm	N/A			
NCI-2015-01907	NCT02595879	Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vulvar Cancer	N/A			
NCI-2015-01910	NCT02595892	Phase 2 Study of VX-970 (NSC# 780162) in Combination with Gemcitabine versus Gemcitabine Alone in Subjects with Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2015-01911	NCT02734537	Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing	N/A			
NCI-2015-01912	NCT02595905	Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer	N/A			
NCI-2015-01913	NCT02595918	A Pilot Study of Neoadjuvant Nivolumab in High-Risk, Non-metastatic, Renal Cell Carcinoma	Inclusion	Leukocytes >= 2,500/mcL	Leukocyte count greater than or equal to 2500 per microliter	(C51948 >= 2500/uL)
NCI-2015-01915	NCT02595931	Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2015-01916	NCT02595944	Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab after Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers	Inclusion	White blood cell (WBC) >= 2000/uL	Leukocyte count greater than or equal to 2000 per microliter	(C51948 >= 2000/uL)
NCI-2015-01917	NCT02642965	A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML)	N/A			
NCI-2015-01918	NCT02750826	Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer	N/A			
NCI-2015-01919	NCT02717455	Phase I Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma	N/A			
NCI-2015-01929	NCT02601209	A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma	N/A			
NCI-2015-02064	NCT02627443	Phase 1 Dose Escalation and Randomized Phase 2 Trial of Carboplatin and Gemcitabine with or without VX-970 in First Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2015-02125	NCT02631733	A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2015-02126	NCT02631746	Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2015-02248	NCT02890355	Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer	N/A			
NCI-2015-02250	NCT02642042	A Phase II Trial of Trametinib with Docetaxel in Patients with KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease following One or Two Prior Systemic Therapies	N/A			
NCI-2015-02253	NCT02823652	COMET - Communication and Education in Tumor Profiling: A Randomized Study of Pre-Test Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling	N/A			
NCI-2016-00050	NCT02785952	A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)	N/A			
NCI-2016-00071	NCT03077451	A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma	Inclusion	Leukocytes >= 3,000/mm^3	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2016-00150	NCT02724579	A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients	N/A			
NCI-2016-00195	NCT02689453	A Phase I Study of Subcutaneous Recombinant Human IL-15 (S.C. Rhil-15) and Alemtuzumab for Patients with Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL)	N/A			
NCI-2016-00203	NCT02713386	A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer	N/A			
NCI-2016-00222	NCT02921256	A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer	N/A			
NCI-2016-00232	NCT02717507	Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial	N/A			
NCI-2016-00233	NCT02927249	A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial	N/A			
NCI-2016-00252	NCT02933489	Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women with Dense Breasts	N/A			
NCI-2016-00264	NCT02728596	A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia-Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)	N/A			
NCI-2016-00325	NCT02728258	A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations	N/A			
NCI-2016-00326	NCT03055013	A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)	N/A			
NCI-2016-00355	NCT02723864	Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination with Cisplatin in Patients with Refractory Solid Tumors	N/A			
NCI-2016-00451	NCT03091660	A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer	N/A			
NCI-2016-00456	NCT02839343	Preoperative Extended Chemotherapy vs. Chemotherapy plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas	N/A			
NCI-2016-00643	NCT02808650	A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors	N/A			
NCI-2016-00666	NCT02775851	A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)	N/A			
NCI-2016-00667	NCT02775812	A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)	N/A			
NCI-2016-00708	NCT02780804	A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma	N/A			
NCI-2016-00787	NCT03030417	A Phase I Study of Indenoisoquinoline LMP744 in Adults with Relapsed Solid Tumors and Lymphomas	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2016-00843	NCT03165721	A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults with Wild Type GIST, Pheochromocytoma and Paraganglioma Associated with Succinate Dehydrogenase Deficiency and HLRCC-Associated Kidney Cancer	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2016-00849	NCT03137771	Maintenance Chemotherapy versus Consolidative Stereotactic Body Radiation Therapy (SBRT) plus Maintenance Chemotherapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial	N/A			
NCI-2016-00926	NCT03033992	Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma	N/A			
NCI-2016-00927	NCT03041701	A Phase I/II Trial of the Insulin-Like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination with the Src Family Kinase (SFK) Inhibitor Dasatinib in Patients with Embryonal and Alveolar Rhabdomyosarcoma	N/A			
NCI-2016-00963	NCT03070886	Phase II-III Trial of Adjuvant Radiotherapy following Radical Prostatectomy with or without Adjuvant Docetaxel	N/A			
NCI-2016-00973	NCT02828358	A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement	N/A			
NCI-2016-01040	NCT03141684	A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma	Inclusion	Leukocytes >= 2,500/mcL	Leukocyte count greater than or equal to 2500 per microliter	(C51948 >= 2500/uL)
NCI-2016-01041	NCT02834013	DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors	N/A			
NCI-2016-01081	NCT02839707	A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer	N/A			
NCI-2016-01087	NCT02839720	Pilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults with Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (CNF)	N/A			
NCI-2016-01094	NCT03109301	A Phase II Trial of the Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Patients with NF1-Mutated Gastrointestinal Stromal Tumors (GIST)	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2016-01104	NCT02844816	Phase II Trial of Atezolizumab in BCG-Unresponsive Non-muscle Invasive Bladder Cancer	N/A			
NCI-2016-01105	NCT02887521	Pulmonary Rehabilitation before Lung Cancer Resection	N/A			
NCI-2016-01110	NCT02900976	A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-Specific Cytotoxic T-Lymphocytes (LMP-TC) in Pediatric Solid Organ Recipients (SOT) with EBV-Positive CD20-Positive Post-transplant Lymphoproliferative Disease (PTLD)	N/A			
NCI-2016-01130	NCT02849496	A Phase II Multiple-Arm, Open-Label, Randomized Study of PARP Inhibition (Veliparib; ABT-888) and Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) Either Alone or in Combination in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC)	N/A			
NCI-2016-01232	NCT02862275	A Pilot Study of Atezolizumab (MPDL3280A) following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies	N/A			
NCI-2016-01258	NCT02867592	Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors	N/A			
NCI-2016-01300	NCT02879695	A Phase 1 Study of Blinatumomab in Combination with Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients with Poor-Risk, Relapsed or Refractory CD19+ Precursor B-lymphoblastic Leukemia	N/A			
NCI-2016-01301	NCT02883062	Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, with or without Atezolizumab in Triple Negative Breast Cancer (TNBC)	Inclusion	Leukocytes >= 2,500/mcL	Leukocyte count greater than or equal to 2500 per microliter	(C51948 >= 2500/uL)
NCI-2016-01325	NCT02888743	A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic Colorectal and NSCLC	N/A			
NCI-2016-01326	NCT02890329	A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia	N/A			
NCI-2016-01346	NCT02893917	A Randomized Phase 2 Study of Cediranib in Combination with Olaparib Versus Olaparib Alone in Men with Metastatic Castration Resistant Prostate Cancer	N/A			
NCI-2016-01356	NCT02893930	A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)	Inclusion	Leukocytes >= 3,000/mm^3	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2016-01357	NCT03115333	Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma	N/A			
NCI-2016-01363	NCT02899728	A Phase II Study of Olaparib plus Cediranib in Combination with Standard Therapy for Small Cell Lung Cancer	Inclusion	White blood cell count (WBC) >= 3 x 10^9/L	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2016-01364	NCT02898207	A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors with Expansion in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2016-01403	NCT03267433	A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission	N/A			
NCI-2016-01412	NCT02975882	A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan	N/A			
NCI-2016-01417	NCT02912559	Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair	N/A			
NCI-2016-01430	NCT02921269	A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination with Bevacizumab in Patients with Recurrent, Persistent, or Metastatic Cervical Cancer	N/A			
NCI-2016-01461	NCT02923778	A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma	N/A			
NCI-2016-01494	NCT02981628	A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)	N/A			
NCI-2016-01501	NCT02936752	A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination with the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients with Myelodysplastic Syndromes after DNA Methyltransferase Inhibitor Therapy Failure	N/A			
NCI-2016-01502	NCT02305654	InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)	N/A			
NCI-2016-01588	NCT03007147	International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones	N/A			
NCI-2016-01595	NCT02954874	A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with â‰¥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy	N/A			
NCI-2016-01597	NCT03373760	A Phase II Study of MEDI4736 (Durvalumab) plus Tremelimumab as Therapy for Patients with Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)	N/A			
NCI-2016-01619	NCT03180268	Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma	N/A			
NCI-2016-01698	NCT02965716	A Phase II Study of Combining T-VEC (NSC-785349) and Pembrolizumab (NSC-776864) in Patients with Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy	N/A			
NCI-2016-01733	NCT02971501	A Phase II Trial of AZD9291 (Osimertinib) with or without Bevacizumab in Patients with EGFR Mutation Positive NSCLC and Brain Metastases	N/A			
NCI-2016-01769	NCT02974621	A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients with Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2016-01771	NCT03274687	A Randomized Phase III Trial of Hypofractionated Post-prostatectomy Radiation Therapy (HYPORT) versus Conventional Post-prostatectomy Radiation Therapy (COPORT)	N/A			
NCI-2016-01804	NCT02978625	A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors	N/A			
NCI-2016-01825	NCT03188393	A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery	N/A			
NCI-2016-01844	NCT03300544	A Phase I Study of Tailmogene Laheparepvec (Talimogene Laherparepvec) with Neoadjuvant Chemotherapy and Radiation in Adenocarcinoma of the Rectum	N/A			
NCI-2016-01847	NCT03250299	Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL101553 in Combination with Standard Radiation in Patients with MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma	N/A			
NCI-2016-01909	NCT02993146	Phase 1 and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2-Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases	Inclusion	Leukocytes >= 3,000/mcL	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
NCI-2016-01981	NCT03150693	A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL	N/A			
NCI-2016-02009	NCT03186898	A Phase III Randomized Trial of Protons versus Photons for Hepatocellular Carcinoma	N/A			
NCI-2016-02060	NCT03216499	Single-Arm, Open-Label Phase II Efficacy Study of First-in-Class HIF2-Alpha Inhibitor, PT2385, for Patients with Recurrent Glioblastoma	N/A			
NCI-2017-00009	NCT03269669	Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma	N/A			
NCI-2017-00058	NCT03018249	A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Depo-Provera (Medroxyprogesterone Acetate) (NSC #26386) Compared to Depo-Provera plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus	N/A			
NCI-2017-00105	NCT03033576	A Phase II Randomized Study of Nivolumab (NSC-732442) with Ipilimumab (NSC-748726) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent	N/A			
NCI-2017-00135	NCT03377556 	A Phase II Study of Talazoparib (BMN 673) in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)	N/A			
NCI-2017-00178	NCT03067181	A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors	N/A			
NCI-2017-00203	NCT03180502	A Phase II Randomized Trial of Proton vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients with IDH Mutant, Low to Intermediate Grade Gliomas	N/A			
NCI-2017-00712	NCT03148275	A Non-randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma	N/A			
NCI-2017-00766	NCT03233204	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes	N/A			
NCI-2017-01030	NCT03206047	A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer	Inclusion	Leukocytes >= 2,500/mcL	Leukocyte count greater than or equal to 2500 per microliter	(C51948 >= 2500/uL)
NCI-2017-01111	NCT03233191	Tomosynthesis Mammographic Imaging Screening Trial (TMIST)	N/A			
NCI-2017-01243	NCT03213652	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations	N/A			
NCI-2017-01244	NCT03220035	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations	N/A			
NCI-2017-01245	NCT03213665	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex	N/A			
NCI-2017-01249	NCT03213678	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors	N/A			
NCI-2017-01250	NCT03213691	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients with Tumors Harboring Activating MAPK Pathway Mutations	N/A			
NCI-2017-01251	NCT03155620	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol	N/A			
NCI-2017-01264	NCT03213704	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions	N/A			
NCI-2017-01425	NCT03244384	Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) versus Observation	Inclusion	Leukocytes >= 3,000/ mm^3	Leukocyte count greater than or equal to 3000 per microliter	(C51948 >= 3000/uL)
